Form 4: Integra LifeSciences Officer Reports Stock Transactions

Jeffrey Mosebrook, SVP of Finance at Integra LifeSciences, reported the acquisition of restricted stock units and disposition of common stock.

Summary

• Jeffrey Mosebrook, SVP, Fin & Princ Acct Officer of Integra LifeSciences Holdings Corp (IART), reported transactions in company securities.
• Disposed of 341 shares of Common Stock at a price of $9.55 per share on March 10, 2026.
• Disposed of 806 shares of Common Stock at a price of $9.61 per share on March 11, 2026.
• Acquired 15,957 Restricted Stock Units (RSUs) on March 11, 2026, with a $0 acquisition price.
• Following these reported transactions, Mosebrook directly owns 35,453 shares of Common Stock and 15,957 Restricted Stock Units.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine insider transaction report. The grant of restricted stock units is a positive for executive alignment, while the dispositions are likely tax-related and not indicative of negative sentiment.

Positives

• The grant of 15,957 Restricted Stock Units to a key executive aligns management's long-term interests with shareholder value.

Negatives

• Disposition of 1,147 shares of common stock by a key executive, likely for tax withholding purposes related to RSU vesting, which is a routine event.

Future Outlook

The 15,957 Restricted Stock Units granted on March 11, 2026, are scheduled to vest over three years: 33% on the first anniversary, 33% on the second anniversary, and 34% on the third anniversary of the grant date.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions and do not typically provide broader industry context. This specific filing reflects routine executive compensation and tax-related share dispositions.

Stakeholder Impact

• Shareholders: The RSU grant aligns executive interests with long-term shareholder value. The dispositions are minor and likely tax-related, having negligible impact.

Next Steps

• Vesting of 33% of the 15,957 Restricted Stock Units on March 11, 2027.
• Vesting of 33% of the 15,957 Restricted Stock Units on March 11, 2028.
• Vesting of 34% of the 15,957 Restricted Stock Units on March 11, 2029.

Key Dates

Keywords

Integra LifeSciences, IART, Jeffrey Mosebrook, Form 4, Insider Trading, Restricted Stock Units, RSU, Common Stock, Executive Compensation, Beneficial Ownership